{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:52:25Z","timestamp":1792907545479,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","award":["NCT02000089"],"award-info":[{"award-number":["NCT02000089"]}],"id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.breast.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T12:04:07Z","timestamp":1655553847000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-5432","authenticated-orcid":false,"given":"R.","family":"Graffeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Q.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-2128","authenticated-orcid":false,"given":"B.","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4824","authenticated-orcid":false,"given":"A.H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.breast.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jmedgenet-2017-105195","article-title":"Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population","volume":"55","author":"Manchanda","year":"2018","journal-title":"J Med Genet"},{"issue":"18","key":"10.1016\/j.breast.2022.06.003_bib3","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.breast.2022.06.003_bib4","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.21.00999","article-title":"Management of women with breast cancer and pathogenic variants in genes other than BRCA1 or BRCA2","volume":"39","author":"Robson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.06.003_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.breast.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2022.06.003_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djq055","article-title":"Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study","volume":"102","author":"Bernstein","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.breast.2022.06.003_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2022.06.003_bib12","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.breast.2022.06.003_bib15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"Tbcrc 031: randomized phase II study of neoadjuvant cisplatin versus Doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2022.06.003_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.breast.2022.06.003_bib17","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"Tbcrc 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.06.003_bib18","series-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","author":"Tutt","year":"2021"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJMe2035083","article-title":"Which genes for hereditary breast cancer?","volume":"384","author":"Narod","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib23","first-page":"573","article-title":"The incidence and gene frequency of ataxia-telangiectasia in the United States","volume":"39","author":"Swift","year":"1986","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.breast.2022.06.003_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"issue":"18","key":"10.1016\/j.breast.2022.06.003_bib25","first-page":"1804","article-title":"DNA-repair gene mutations in metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2022.06.003_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","article-title":"ATM mutations in patients with hereditary pancreatic cancer","volume":"2","author":"Roberts","year":"2012","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.breast.2022.06.003_bib28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2022.06.003_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.breast.2022.06.003_bib30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ng.3342","article-title":"Loss-of-function variants in ATM confer risk of gastric cancer","volume":"47","author":"Helgason","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.breast.2022.06.003_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ajhg.2018.01.018","article-title":"Inherited DNA-repair defects in colorectal cancer","volume":"102","author":"AlDubayan","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","article-title":"A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","volume":"22","author":"LaDuca","year":"2020","journal-title":"Genet Med"},{"issue":"23","key":"10.1016\/j.breast.2022.06.003_bib33","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2022.06.003_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jmedgenet-2015-103398","article-title":"Multigene testing of moderate-risk genes: be mindful of the missense","volume":"53","author":"Young","year":"2016","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.breast.2022.06.003_bib35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/jmedgenet-2017-104588","article-title":"Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks","volume":"54","author":"Decker","year":"2017","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib36","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr2919","article-title":"Rare variants in the ATM gene and risk of breast cancer","volume":"13","author":"Goldgar","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.breast.2022.06.003_bib37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/09553002.2017.1344363","article-title":"ATM, radiation, and the risk of second primary breast cancer","volume":"93","author":"Bernstein","year":"2017","journal-title":"Int J Radiat Biol"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev Res"},{"issue":"10","key":"10.1016\/j.breast.2022.06.003_bib39","doi-asserted-by":"crossref","first-page":"e1409","DOI":"10.1002\/mgg3.1409","article-title":"Severe reaction to radiotherapy provoked by hypomorphic germline mutations in ATM (ataxia-telangiectasia mutated gene)","volume":"8","author":"Asadollahi","year":"2020","journal-title":"Mol Genet Genomic Med"},{"issue":"22","key":"10.1016\/j.breast.2022.06.003_bib40","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.06.003_bib42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","article-title":"Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance","volume":"155","author":"Canto","year":"2018","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.breast.2022.06.003_bib44","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.06.003_bib45","doi-asserted-by":"crossref","first-page":"dju091","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2022.06.003_bib46","doi-asserted-by":"crossref","first-page":"51 e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"28","key":"10.1016\/j.breast.2022.06.003_bib47","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ijc.20299","article-title":"CHEK2 variant I157T may be associated with increased breast cancer risk","volume":"111","author":"Kilpivaara","year":"2004","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.breast.2022.06.003_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2011-100380","article-title":"CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women","volume":"48","author":"Adank","year":"2011","journal-title":"J Med Genet"},{"issue":"15_suppl","key":"10.1016\/j.breast.2022.06.003_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.1539","article-title":"Risk of HER2-positive breast cancer among germline CHEK2 mutation carriers with breast cancer","volume":"34","author":"Ramamurthy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/gim.2016.147","article-title":"Genetic modifiers of CHEK2*1100delC-associated breast cancer risk","volume":"19","author":"Muranen","year":"2017","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.breast.2022.06.003_bib52","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/1055-9965.EPI-18-1102","article-title":"Frequency of pathogenic germline variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in sporadic lobular breast cancer","volume":"28","author":"Petridis","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-2865-2","article-title":"Survival from breast cancer in patients with CHEK2 mutations","volume":"144","author":"Huzarski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"35","key":"10.1016\/j.breast.2022.06.003_bib54","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","article-title":"A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","volume":"22","author":"LaDuca","year":"2020","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.breast.2022.06.003_bib56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ygyno.2006.05.040","article-title":"CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors","volume":"102","author":"Szymanska-Pasternak","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.breast.2022.06.003_bib57","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/gim.2018.12","article-title":"A counseling framework for moderate-penetrance colorectal cancer susceptibility genes","volume":"20","author":"Katona","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib58","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/gutjnl-2012-304121","article-title":"Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence","volume":"63","author":"Ma","year":"2014","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.breast.2022.06.003_bib59","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.06.003_bib60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2022.06.003_bib61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2022.06.003_bib62","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.29426","article-title":"CHEK2 mutations and the risk of papillary thyroid cancer","volume":"137","author":"Siolek","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamaoncol.2018.6477","article-title":"Association of inherited pathogenic variants in checkpoint kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors","volume":"5","author":"AlDubayan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.breast.2022.06.003_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","article-title":"High risk of breast cancer in women with biallelic pathogenic variants in CHEK2","volume":"180","author":"Rainville","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng1296-430","article-title":"Identification of a RING protein that can interact in vivo with the BRCA1 gene product","volume":"14","author":"Wu","year":"1996","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.breast.2022.06.003_bib66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-011-1403-8","article-title":"Cancer predisposing BARD1 mutations in breast-ovarian cancer families","volume":"131","author":"Ratajska","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2022.06.003_bib67","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2022.06.003_bib68","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.breast.2022.06.003_bib69","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2022.06.003_bib70","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ng.374","article-title":"Common variations in BARD1 influence susceptibility to high-risk neuroblastoma","volume":"41","author":"Capasso","year":"2009","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.breast.2022.06.003_bib71","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.semcdb.2011.07.019","article-title":"RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis","volume":"22","author":"Suwaki","year":"2011","journal-title":"Semin Cell Dev Biol"},{"issue":"9","key":"10.1016\/j.breast.2022.06.003_bib72","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.breast.2022.06.003_bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jmedgenet-2012-100852","article-title":"A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer","volume":"49","author":"Pelttari","year":"2012","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.breast.2022.06.003_bib74","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/annonc\/mdy338","article-title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1\/2-negative breast cancers","volume":"29","author":"Chen","year":"2018","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.breast.2022.06.003_bib75","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2022.06.003_bib76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.breast.2022.06.003_bib77","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:45:01Z","timestamp":1760777101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977622001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":75,"alternative-id":["S0960977622001047"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.06.003","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}